Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics - 1 Jan 2026

Baune Bernhard T

Abstract excerpt

Major depressive disorder (MDD) is treated largely by trial and error, despite marked interindividual variation in antidepressant exposure, efficacy and tolerability. Pharmacogenomics (PGx) has therefore been proposed as a route to stratified antidepressant treatment. This Review asks whether current evidence supports that claim by distinguishing actionable drug-gene guidance, clinical utility in broad trial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Cytochrome P-450 CYP2B6
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Major Depressive Disorder

Share to Pharmacogenetics

Share to Selective Serotonin Reuptake Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 42299141
DOI: 10.1080/14622416.2026.2686866
PMCID: PMC13374748

Genes

CYP2B6
CYP2C19
HTR2A
SLC6A4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.PMID 42299141Read ↗

A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response OutcomesSemantic proximity Read ↗

A Framework to Quantify Disparities in Pharmacogenomic Treatment Concordance and Drug Response Outcomes.Semantic proximity Read ↗

Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Semantic proximity Read ↗

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and FutureSemantic proximity Read ↗

A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder.Semantic proximity Read ↗

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read ↗

Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test.Semantic proximity Read ↗

Depression and Pharmacogenetics.Semantic proximity Read ↗

Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical StudiesSemantic proximity Read ↗

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responsesSemantic proximity Read ↗

Pharmacogenetics testing for poor response to antidepressants: a transnosographic case seriesSemantic proximity Read ↗

Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.